rabeprazole has been researched along with Hematochezia in 11 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Hematochezia: The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)-induced gastric ulcers compared with proton pump inhibitors (PPIs)." | 9.22 | Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. ( Hasui, T; Inaba, T; Ishida, M; Ishikawa, S; Iwamuro, M; Izumikawa, K; Kagawa, T; Kuraoka, S; Matsuura, M; Sakakihara, I; Sasaki, K; Takahashi, S; Tanaka, S; Wato, M; Yamamoto, K, 2016) |
| "Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)-induced gastric ulcers compared with proton pump inhibitors (PPIs)." | 5.22 | Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. ( Hasui, T; Inaba, T; Ishida, M; Ishikawa, S; Iwamuro, M; Izumikawa, K; Kagawa, T; Kuraoka, S; Matsuura, M; Sakakihara, I; Sasaki, K; Takahashi, S; Tanaka, S; Wato, M; Yamamoto, K, 2016) |
| " PPIs are the mainstay therapeutic agents for prophylaxis against aspirin gastropathy and for acid-related disorders including gastroesophageal reflux disease." | 4.95 | East Asian perspective on the interaction between proton pump inhibitors and clopidogrel. ( Goh, KL; Zou, D, 2017) |
| "Although acid suppressants are needed to attenuate gastrointestinal bleeding (GIB) after percutaneous coronary intervention (PCI), pharmacodynamic interaction between clopidogrel and proton pump inhibitor (PPI) can increase the risk of high platelet reactivity (HPR)." | 1.56 | Influence of rabeprazole and famotidine on pharmacodynamic profile of dual antiplatelet therapy in clopidogrel-sensitive patients: The randomized, prospective, PROTECT trial. ( Ahn, JH; Bae, JS; Hwang, JY; Hwang, SJ; Jang, JY; Jeong, YH; Kang, MG; Kim, KH; Koh, JS; Kwak, CH; Park, JR; Park, Y, 2020) |
| " In 199 patients treated with DAT alone (control group) and 103 patients treated with rabeprazole plus DAT (rabeprazole group), we examined the incidences of GI bleeding and major adverse cardiac events (MACE) including stent thrombosis." | 1.36 | [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study]. ( Chubachi, H; Ikee, R; Miyasaka, Y; Saito, S; Yasu, T, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, JH | 1 |
| Park, Y | 1 |
| Bae, JS | 1 |
| Jang, JY | 1 |
| Kim, KH | 1 |
| Kang, MG | 1 |
| Koh, JS | 1 |
| Park, JR | 1 |
| Hwang, SJ | 1 |
| Kwak, CH | 1 |
| Hwang, JY | 1 |
| Jeong, YH | 1 |
| Baeg, MK | 1 |
| Choi, MG | 1 |
| Moon, SJ | 1 |
| Lim, CH | 1 |
| Kim, JS | 1 |
| Cho, YK | 1 |
| Park, JM | 1 |
| Lee, IS | 1 |
| Kim, SW | 1 |
| Choi, KY | 1 |
| Hikichi, T | 1 |
| Sato, M | 1 |
| Watanabe, K | 1 |
| Nakamura, J | 1 |
| Takagi, T | 1 |
| Suzuki, R | 1 |
| Sugimoto, M | 1 |
| Waragai, Y | 1 |
| Kikuchi, H | 1 |
| Konno, N | 1 |
| Ohira, H | 1 |
| Obara, K | 1 |
| Kagawa, T | 1 |
| Iwamuro, M | 1 |
| Ishikawa, S | 1 |
| Ishida, M | 1 |
| Kuraoka, S | 1 |
| Sasaki, K | 1 |
| Sakakihara, I | 1 |
| Izumikawa, K | 1 |
| Yamamoto, K | 1 |
| Takahashi, S | 1 |
| Tanaka, S | 1 |
| Matsuura, M | 1 |
| Hasui, T | 1 |
| Wato, M | 1 |
| Inaba, T | 1 |
| Zou, D | 1 |
| Goh, KL | 1 |
| Yasu, T | 1 |
| Ikee, R | 1 |
| Miyasaka, Y | 1 |
| Chubachi, H | 1 |
| Saito, S | 1 |
| Hata, M | 2 |
| Shiono, M | 2 |
| Sekino, H | 2 |
| Furukawa, H | 2 |
| Sezai, A | 2 |
| Iida, M | 2 |
| Yoshitake, I | 2 |
| Hattori, T | 2 |
| Wakui, S | 2 |
| Soeda, M | 1 |
| Taoka, M | 2 |
| Negishi, N | 2 |
| Sezai, Y | 2 |
| Gon, S | 1 |
| Irie, Y | 1 |
| Takahashi, M | 1 |
| Sung, HY | 1 |
| Kim, JI | 1 |
| Park, YB | 1 |
| Cheung, DY | 1 |
| Cho, SH | 1 |
| Park, SH | 1 |
| Han, JY | 1 |
| Kim, JK | 1 |
| Barada, K | 1 |
| Karrowni, W | 1 |
| Abdallah, M | 1 |
| Shamseddeen, W | 1 |
| Sharara, AI | 1 |
| Dakik, HA | 1 |
1 review available for rabeprazole and Hematochezia
| Article | Year |
|---|---|
East Asian perspective on the interaction between proton pump inhibitors and clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anticoagulants; Asia, Eastern; Asian People; Aspirin; Clopi | 2017 |
4 trials available for rabeprazole and Hematochezia
| Article | Year |
|---|---|
Preprocedural rabeprazole treatment before endoscopic submucosal dissection for gastric neoplasms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Dissection; Female; Gastric Mucosa; Gastrointestinal | 2014 |
Oral rabeprazole administration on a procedure day suppresses bleeding after endoscopic submucosal dissection for gastric neoplasms.
Topics: Adenocarcinoma; Adenoma; Administration, Oral; Aged; Aged, 80 and over; Female; Gastrointestinal Hem | 2014 |
Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.
Topics: Adenoma; Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Female; Gastrointestinal Hemorrhage; | 2016 |
Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cardiac Surgical Procedu | 2005 |
6 other studies available for rabeprazole and Hematochezia
| Article | Year |
|---|---|
Influence of rabeprazole and famotidine on pharmacodynamic profile of dual antiplatelet therapy in clopidogrel-sensitive patients: The randomized, prospective, PROTECT trial.
Topics: Aged; Clopidogrel; Drug Interactions; Famotidine; Female; Gastrointestinal Hemorrhage; Humans; Male; | 2020 |
[Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; | 2010 |
Efficacy of a proton pump inhibitor given in the early postoperative period to relieve symptoms of hiatal hernia after open heart surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Benzimidazoles; Cardiac Sur | 2006 |
Effects of rabeprazole or famotidine during cardiac surgery on perioperative gastric and esophageal pH readings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2006 |
The papilla of Vater just below the pylorus presenting as recurrent duodenal ulcer bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Bile; Bile Ducts; Duodenal Ulcer; | 2007 |
Upper gastrointestinal bleeding in patients with acute coronary syndromes: clinical predictors and prophylactic role of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Aged; Female; Fibrinolytic Agents; | 2008 |